Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/07/2025
• Auteurs : Zacharie Barrou DumontSimon GascoinJordi IngladaAndreas DietzJonas KöhlerMatthieu LafaysseDiego MonteiroCarlo CarmagnolaArthur BayleJean-Pierre DedieuOlivier HagolleP. Choler
• Organismes : Centre d'études spatiales de la biosphère Centre d'études spatiales de la biosphère Centre d'études spatiales de la biosphère Centre National d'Études Spatiales [Toulouse] University Hospital Leipzig = Universitätsklinikum Leipzig Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] Centre d'Etudes de la Neige Centre d'Etudes de la Neige ABEST Horizons Centre d'Etudes de la Neige Laboratoire d'Ecologie Alpine Institut d'Asie Orientale Institut des Géosciences de l’Environnement Centre d'études spatiales de la biosphère Centre National d'Études Spatiales [Toulouse] Laboratoire d'Ecologie Alpine
• Publié dans The Cryosphere le 28/10/2020

---

Résumé : Abstract. Information on the spatial–temporal variability of seasonal snow cover duration over long time periods is critical for studying the responses of mountain ecosystems to climate change. However, this information is often lacking due to the sparse distribution of in situ observations or the lack of adequate remote sensing products. Here, we combined snow cover data from 10 different optical platforms, i.e. SPOT (Satellites Pour l'Observation de la Terre) 1–5, Landsat 5–8, and Sentinel-2A and Sentinel-2B, to build a time series of the annual snow melt-out day (SMOD, i.e. the first day of no snow cover) at 20 m resolution across the French Alps and Pyrenees (43 × 103 km2). We evaluated the pixel-wise accuracy of the computed SMOD using in situ snow measurements at 276 stations. We found that the residuals are unbiased (median error of 1 d) despite a dispersion (RMSE of 28 d), which suggests that this dataset can be used to study SMOD trends after spatial aggregation. We found average reductions of 21.4 d (5.78 d per decade) over the French Alps and 16 d (4.33 d per decade) over the Pyrenees over the period 1986–2023. The SMOD reduction is robust and significant in most parts of the French Alps and can reach 1 month above 3000 m. The trends are less consistent and more spatially variable in the Pyrenees. This dataset is available for future studies of mountain ecosystem changes and is updated every year using Sentinel-2 data.

---

Fichiers liés : tc-19-2407-2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/07/2025
• Auteurs : Maxence JamesElise NexerAlexandra GirondéCéline Masclaux‐daubresseAnne MarmagneJacques TrouveriePhilippe Etienne
• Organismes : Université de Caen Normandie Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Ecophysiologie Végétale, Agronomie et Nutritions NCS Ecophysiologie Végétale, Agronomie et Nutritions NCS Université de Caen Normandie
• Publié dans Planta le 31/10/2020

---

Résumé :

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Benoit YouSebastien CouraudPhilippe CeruseLionel BadetPhilippe PaparelAlice DurandMarielle GuilletPhilippe MerleGaelle LescuyerCharles-André PhilipFrancois DucrayMathieu PiocheLionel KarlinJean-Christophe LifanteOlivier GlehenPierre-Adrien BolzeMarion ChauvenetCarole Langlois-JacquesFabien SubtilMarie PiecykAurore CarrotDominique JoubertAlexandre PrieurBerengere VireSara CalattiniLea Payen
• Organismes : Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Femme Mère Enfant [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hôpital Edouard Herriot [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Research on Healthcare Performance Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre Hospitalier Lyon Sud [CHU - HCL] Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Hospices Civils de Lyon Service de Biostatistiques [Lyon] Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Institut de Cancérologie des Hospices Civils de Lyon Centre pour l'innovation en cancérologie de Lyon Laboratoire de Biologie Médicale MultiSites [Bron]
• Publié dans Biomarker Research le 25/10/2020

---

Résumé : Abstract Background hPG 80 (circulating progastrin), initially recognized for its oncogenic properties due to its direct link to the Wnt signaling pathway, is secreted by cancer cells and detectable in the blood of cancer patients. The ONCOPRO centralized case-control study (NCT03787056) was designed to prospectively evaluate the diagnostic utility of hPG 80 in patients with 16 different types of cancer. Methods hPG 80 levels were measured in 421 patients with 16 newly diagnosed cancers (median age 65.6 years old) using the DxPG80.Lab kit (Biodena Care). The diagnostic performance of hPG 80 (the primary endpoint) was assessed by comparing baseline hPG 80 levels in cancer patients with those of 330 asymptomatic aged-matched healthy subjects from the general population. Results Between 2018 and 2022, a total of 506 cancer patients were enrolled in the study, with 421 assessable across 16 distinct cancer cohorts. hPG 80 concentrations were significantly higher in cancer patients compared to the healthy population (median 3.8 [IQR: 1.0-11.1] vs. 1.9 [IQR: 0.6–4.2] pM, P < 0.0001). hPG80 levels were not impacted by renal failure, liver dysfunction, or cancer-associated inflammation. The diagnostic accuracy in cancer patients was ROC AUC 0.63, 95% CI = [0.59–0.67]. The highest diagnostic accuracy was seen in patients with lung cancer (AUC 0.75, 95% CI [0.68–0.82]; specificity = 88% for hPG 80 > 7.73 pM in patients aged > 58 years old) and hepatocellular carcinoma HCC (ROC AUC 0.75, 95% CI [0.66-083]; specificity = 88% for hPG 80 > 7.73 pM in patients aged > 58 years old). Conclusions This large prospective study confirms that cancer patients have significantly higher hPG 80 blood concentration compared to the healthy population. Incorporating this straightforward ELISA assay into screening programs is warranted. Trial registration NCT03787056.

---

Fichiers liés : 40364_2025_Article_793.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/07/2025
• Auteurs : Jean-Charles LeclercT LeA BaudElea GonthierS DittamiF ThomasG TanguyA NicolleMarine MoalM GonzalezAurore RaouxR. Crec’hriouCaroline BroudinCéline HoubinLucille CaradecL BlondelE LegeayD PottinS LoiselL. SevinJérôme CoudretAline MignéDominique DavoultThomas BurelG SchiresJean-Philippe PezyP PotinÉric Thiébaut
• Organismes : Morphodynamique Continentale et Côtière Station biologique de Roscoff = Roscoff Marine Station Fédération de recherche de Roscoff Station biologique de Roscoff = Roscoff Marine Station OSU Stations marines Fédération de recherche de Roscoff Adaptation et diversité en milieu marin Adaptation et diversité en milieu marin Fédération de recherche de Roscoff Station biologique de Roscoff = Roscoff Marine Station Adaptation et diversité en milieu marin

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Anna Maria AuxiliaEmilie OliéJonathan DuboisEnrico CapuzziValérie AubinBruno AouizerateFrank BellivierRaoul BelzeauxCaroline DubertretDominique JanuelEmmanuel HaffenAntoine LefrereAgnès PelletierMircea PolosanRoman ReyP. RouxLudovic SamalinRaymund SchwanMichel WalterAntoine YrondiPierre-Michel LlorcaMarion LeboyerB EtainPhilippe Courtet
• Organismes : Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Fondation FondaMental [Créteil] Institut de Génomique Fonctionnelle Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Institut de Génomique Fonctionnelle Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Fondazione IRCCS San Gerardo dei Tintori [Monza, Italy] Fondation FondaMental [Créteil] Centre Hospitalier Princesse Grace Centre hospitalier Charles Perrens [Bordeaux] Nutrition et Neurobiologie intégrée Fondation FondaMental [Créteil] Optimisation thérapeutique en Neuropsychopharmacologie Fondation FondaMental [Créteil] Hôpital Lariboisière-Fernand-Widal [APHP] Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Fondation FondaMental [Créteil] Hôpital Louis Mourier - AP-HP [Colombes] Institut de psychiatrie et neurosciences de Paris Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Centre de Recherche Clinique [Neuilly-sur-Marne] Centre d'Investigation Clinique de Besançon Fondation FondaMental [Créteil] Laboratoire de recherches Intégratives en Neurosciences et psychologie Cognitive Assistance Publique - Hôpitaux de Marseille Institut de Neurosciences de la Timone Fondation FondaMental [Créteil] Institut Mondor de Recherche Biomédicale CHU Henri Mondor [Créteil] Fondation FondaMental [Créteil] Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Fondation FondaMental [Créteil] [GIN] Grenoble Institut des Neurosciences Fondation FondaMental [Créteil] Centre Hospitalier le Vinatier [Bron] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation FondaMental [Créteil] Centre de recherche en épidémiologie et santé des populations Centre Hospitalier de Versailles André Mignot Fondation FondaMental [Créteil] Institut Pascal CHU Clermont-Ferrand Fondation FondaMental [Créteil] Centre Psychothérapique de Nancy [Laxou] Université de Lorraine Hopital de Bohars - CHRU Brest Fondation FondaMental [Créteil] Centre Hospitalier Universitaire de Toulouse Fondation FondaMental [Créteil] Toulouse NeuroImaging Center Fondation FondaMental [Créteil] CHU Clermont-Ferrand Institut Pascal Fondation FondaMental [Créteil] CHU Henri Mondor [Créteil] Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie = Addiction And Psychiatry Transformation with Precision Medicine [Créteil, France] Institut Mondor de Recherche Biomédicale Optimisation thérapeutique en Neuropsychopharmacologie GHU AP-HP Nord - Université Paris Cité Fondation FondaMental [Créteil] Fondation FondaMental [Créteil] Département de Psychiatrie adulte [Hôpital de la Colombière - CHU Montpellier] Institut de Génomique Fonctionnelle
• Publié dans European Psychiatry le 23/10/2020

---

Résumé : Introduction: Suicidal behaviors (SB) in bipolar disorder (BD) are major adverse outcomes that may influence disease progression. While staging models exist for psychiatric disorders, none include suicide. This study aims to stratify suicidal risk in BD, propose a staging model for SB, and assess its clinical utility. Methods: Participants from the FondaMental Advanced Center of Expertise for Bipolar Disorder (FACE-BD) cohort were categorised into five stages (St) based on SB: St0 (no suicidal ideation [SI]), St1 (SI but no suicide attempt [SA]), St2a (non-severe/violent SA), St2b (severe /violent SA), and St3 (multiple SAs). Stages were analysed based on demographic, clinical, cognitive, and biological characteristics using logistic regression. Results: Key differences emerged between stages. St1 showed longer untreated illness and higher lability and lower functioning than St0. St2a was linked to anxiety, substance use disorders, and longer disorder duration, while male gender and lithium bitherapy were protective. St2b exhibited shorter untreated illness and higher childhood trauma (CTQ) scores, with male gender and alcohol use as risk factors. St3 was associated with BD-II, alcohol use, longer disorder duration, and more depressive episodes, but less anxiety. No biochemical or cognitive differences were found across stages. The model was significantly associated with SA occurrence (LRT = 28.74, p < 0.0001). Conclusion: This staging model for suicidality in BD provides a multifaceted approach to risk stratification and predictive insights, although further refinement is needed.

---

Fichiers liés : Auxilia et al 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Fawzi KerkouriRomain EschalierSamir FarehChristelle MarquiéMina Ait SaidWalid AmaraFrédéric AnselmeMarc BadozNathalie BeharPierre BordacharRim El BouazzaouiLaure Champ RigotMichel ChauvinPhilippe ChevalierAntoine da CostaPascal DefayeJean Claude DeharoLaurent FauchierEstelle GandjbakhchEdouard GitenayJean-Baptiste GourraudCharles GuenanciaMaxime de GuillebonBenoît Guy-MoyatAlexis HermidaJérôme HourdainPeggy JaconPierre KhattarMikael LaredoLaurence JeselNicolas LelloucheChristophe LeclercqVincent MansouratiPhilippe MauryPierre MondolyJean-Luc PasquiéMichaël PeyrolBertrand PierreSylvain PlouxCharlotte PotelleNicolas SadoulJean Marc SellalEmilie VarletRodrigue GarciaVincent ProbstSerge BovedaEloi Marijon
• Organismes : Centre Hospitalier Régional Universitaire de Brest Optimisation des régulations physiologiques Service de cardiologie [CHU HEGP] Paris-Centre de Recherche Cardiovasculaire CHU Clermont-Ferrand Hôpital de la Croix-Rousse [CHU - HCL] Centre Hospitalier Régional Universitaire [CHU Lille] Hôpital Privé Jacques Cartier [Massy] Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Service de Cardiologie [CHU Rouen] Service de cardiologie [CHRU de Besançon] Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes] Département de cardiologie Centre Hospitalier Libourne Service de cardiologie et de pathologie vasculaire [CHU Caen] Clinique de l'Orangerie [Strasbourg] Services de Pneumologie, Exploration Fonctionnelle Respiratoire et Cardiologie Service de Cardiologie [CHU Saint-Etienne] Département de cardiologie [CHU de Grenoble] Département de Cardiologie [Hôpital de la Timone - APHM] Centre Hospitalier Régional Universitaire de Tours Institut de cardiologie [CHU Pitié-Salpêtrière] Departement de Cardiologie [Hôpital Saint-Joseph - Marseille] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Service de Cardiologie [CHU de Dijon] Centre hospitalier de Pau Service de cardiologie [CHU Limoges] Neurologie [CHU Amiens] Périnatalité et Risques Toxiques - UMR INERIS_I 1 UPJV Département de Cardiologie [Hôpital de la Timone - APHM] Département de cardiologie [CHU de Grenoble] Groupe Hospitalier Bretagne Sud Institut de cardiologie [CHU Pitié-Salpêtrière] Centre Hospitalier Universitaire [Strasbourg] Service de Cardiologie [CHU Henri Mondor] Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes] Centre Hospitalier Régional Universitaire de Brest Optimisation des régulations physiologiques Service Cardiologie [CHU Toulouse] Service Cardiologie [CHU Toulouse] Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Service de cardiologie [Hôpital Nord - APHM] Centre Hospitalier Régional Universitaire de Tours Département de cardiologie Centre Hospitalier Régional Universitaire [CHU Lille] Service de Cardiologie [CHRU Nancy] Service de Cardiologie [CHRU Nancy] Service de cardiologie [CHU HEGP] Service de cardiologie [CHU de Poitiers] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Clinique Pasteur [Toulouse] Service de cardiologie [CHU HEGP]
• Publié dans Journal of the American College of Cardiology le 26/10/2020

---

Résumé : Background: Defibrillation testing (DT) remains recommended during subcutaneous implantable cardioverter defibrillator (S-ICD) implantation due to limited supporting evidence. Objectives: The objective of this study was to evaluate the long-term impact of DT during S-ICD implantation. Methods: The HONEST (coHOrte fraNcaise des dEfibrillateurs Sous cuTanés) study is a nationwide, ongoing observational study, including all S-ICD recipients in France (2012-2019). Five-year endpoints were centrally adjudicated, and propensity score-weighted analyses compared outcomes by DT status. Results: Among 4,924 patients, DT was performed in 4,066 (82.6%), decreasing from 85.4% (2012-2014) to 66.9% in 2019 (P < 0.001). Nontested patients were older (51.2 vs 49.6 years; P = 0.007), had lower left ventricular ejection fraction (37.6% vs 43.3%; P < 0.001), and were more frequently implanted for primary prevention (68.0% vs 62.4%; P = 0.002) and structural heart disease (84.9% vs 76.8%; P < 0.001). DT-related complications occurred in 0.1%, including 2 deaths. Failure rate was 1.0%, with 87.8% undergoing corrective reinterventions. Independent predictors of DT failure were elevated shock impedance (≥89 Ω; OR: 4.60; 95% CI: 2.32-9.66; P < 0.001) and obesity (body mass index ≥30 kg/m2; OR: 2.17; 95% CI: 1.01-4.55; P = 0.007). After adjustment, DT omission was not associated with increased risks of overall mortality (HR: 1.17; 95% CI: 0.86-1.61; P = 0.313), cardiovascular mortality (HR: 1.04; 95% CI: 0.70-1.56; P = 0.846), sudden cardiac death (HR: 0.27; 95% CI: 0.04-1.72; P = 0.167), and appropriate (HR: 1.01; 95% CI: 0.78-1.30; P = 0.945) or inappropriate shocks (HR: 0.98; 95% CI: 0.78-1.23; P = 0.865). Combined rates of ineffective shocks or undetected ventricular arrhythmias were similar (0.05 vs 0.06 per 100 person-years). Conclusions: Our findings suggest that DT can be safely omitted in the majority of S-ICD recipients, whereas selective DT may be considered in higher-risk subgroups. (S-ICD French Cohort Study (HONEST); NCT05302115).

---

Fichiers liés : 2025 Kerkouri et al., Defibrillation Testing.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Maxence JamesJacques TrouverieBenoit BernayAnne MarmagneFabien ChardonMarin-Pierre GéminPhilippe EtienneCéline Masclaux‐daubresse
• Organismes : Université de Caen Normandie Ecophysiologie Végétale, Agronomie et Nutritions NCS Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Ecophysiologie Végétale, Agronomie et Nutritions NCS Université de Caen Normandie Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans The Plant Journal le 26/10/2020

---

Résumé :

---

Fichiers liés : 2025 - James - V‐ATPases and amino acid catabolism are strongly disturbed in the roots of autophagy.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Matthieu LegrandEdouard JullienAntoine KimmounGuillaume GeriHafid Ait-OufellaStanislas AbrardSamuel GaugainFanny BounesPhilippe GuerciJulien PottecherMatthieu JammeYves Poncelin de RaucourtDamien BarraudJean-Michel ConstantinWilliam JuguetSigismond LasockiRomain SonnevilleJuliette AudibertGaëtan PlantefèveOlivier EllrodtAnne-Laure FedouMarc LeoneLaurent LefebvreAdrien AuvetDavid ChenEric VicautFrançois Dépret
• Organismes : University of California [San Francisco] Investigation Network Initiative - Cardiovascular and Rénal Clinical Trialist Hôpital Ambroise Paré [AP-HP] Université de Versailles Saint-Quentin-en-Yvelines Investigation Network Initiative - Cardiovascular and Rénal Clinical Trialist Défaillance Cardiovasculaire Aiguë et Chronique French-Clinical Research Infrastructure Network - F-CRIN [Paris] Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] CHU Saint-Antoine [AP-HP] Hôpital Edouard Herriot [CHU - HCL] Hôpital Lariboisière-Fernand-Widal [APHP] Centre Hospitalier Universitaire de Toulouse Investigation Network Initiative - Cardiovascular and Rénal Clinical Trialist Centre Hospitalier Régional Universitaire de Nancy Défaillance Cardiovasculaire Aiguë et Chronique Centre Hospitalier Universitaire [Strasbourg] Ramsay Santé Centre Hospitalier de Bourg en Bresse Centre hospitalier régional de Metz-Thionville CHU Pitié-Salpêtrière [AP-HP] Hôpital Avicenne [AP-HP] Centre Hospitalier Universitaire d'Angers Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hôpitaux de Chartres [Chartres] Centre hospitalier Victor Dupouy [Centre hospitalier d'Argenteuil] Centre Hospitalier de Melun Centre Hospitalier Universitaire Dupuytren 1 et 2 Hôpital Nord [CHU - APHM] Centre Hospitalier d'Aix en Provence [Aix-en-Provence] Centre Hospitalier Dax - Côte d'Argent University of California [San Francisco] Investigation Network Initiative - Cardiovascular and Rénal Clinical Trialist Hôpital Lariboisière-Fernand-Widal [APHP] Marqueurs cardiovasculaires en situation de stress Investigation Network Initiative - Cardiovascular and Rénal Clinical Trialist Assistance publique - Hôpitaux de Paris (AP-HP)
• Publié dans American Journal of Respiratory and Critical Care Medicine le 26/10/2020

---

Résumé : Rationale: Preclinical and preliminary clinical data suggest that iloprost may improve tissue perfusion in septic shock. However, its effect on organ failure remains unclear. Objectives: To investigate whether iloprost provides organ protection in septic shock with hypoperfusion. Methods: In this multicenter, double-blind, randomized controlled trial, adults with septic shock and persistent hypoperfusion (i.e., increased capillary refill time and/or skin mottling) were randomized to receive a 48-hour intravenous infusion of iloprost or placebo. The primary outcome was the change in the Sequential Organ Failure Assessment (SOFA) score from randomization to Day 7. Secondary outcomes included mortality at Day 28, organ support-free days by Day 28, and mean daily SOFA score. Measurements and Main Results: A total of 240 patients were randomized, and 236 were included in the analysis. Median (IQR) changes in SOFA score were -4 (-7 to 7) in the iloprost group and -5 (-8 to 5) in the placebo group (median difference, 1; 95% CI, 0-3; P = 0.12). At 28 days, 48 patients (42%) had died in the iloprost group and 47 (39%) had died in the placebo group (relative risk, 1.08; 95% CI, 0.80-1.5). The median average SOFA score was 11.2 (7.4-15.9) in the iloprost group, compared with 10.5 (6.8-16.5) in the placebo group (median difference, 0.25; 95% CI, -1.1 to 1.8). Median (95% confidence interval) between-group differences in 28-day ventilation-, vasopressor-, and renal replacement therapy-free survival days were 0 (0-0), 0 (-1 to 1), and 0 (0-0), respectively. Severe adverse events occurred in 15% of patients in the iloprost group and 7% of patients in the placebo group (P = 0.06). Conclusions: Among patients with septic shock and persistent hypoperfusion, iloprost did not reduce the severity of organ failure. Clinical trial registered with www.clinicaltrials.gov (NCT03788837) and EudraCT (2018-001709-10).

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Adrien Ter SchiphorstPierre SenersAnke WoutersNicole YuenMichael MlynashJeremy Josef HeitStephanie KempSøren ChristensenDenis SablotAnne WacongneThibault LaluAude PhilippeCaroline ArquizanVincent CostalatGregory W AlbersMaarten Lansberg
• Organismes : Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Stanford Stroke Center Institut de psychiatrie et neurosciences de Paris Institut de psychiatrie et neurosciences de Paris Stanford Stroke Center Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Catholic University of Leuven = Katholieke Universiteit Leuven Stanford Stroke Center Stanford Stroke Center Stanford University Stanford Stroke Center Stanford Stroke Center Centre Hospitalier Saint Jean de Perpignan Centre Hospitalier Universitaire de Nîmes Centre Hospitalier de Béziers Centre Hospitalier Régional Universitaire [Montpellier] Hôpital Gui de Chauliac [CHU Montpellier] Institut de psychiatrie et neurosciences de Paris Département de Neuroradiologie [CHRU Montpellier] Institut de psychiatrie et neurosciences de Paris Stanford Stroke Center Stanford Stroke Center
• Publié dans Stroke le 31/10/2020

---

Résumé : Background: For patients with acute ischemic stroke due to a large vessel occlusion admitted in primary stroke centers, helicopter transfer to comprehensive stroke centers is often used to expedite access to mechanical thrombectomy. Some studies have suggested that vibrations generated during helicopter transport might enhance intravenous thrombolysis (IVT) efficacy. We aimed to evaluate the impact of helicopter transfer, compared with ground transportation, on interhospital recanalization and functional outcomes. Methods: We conducted a retrospective analysis of 2 prospectively collected cohorts of anterior circulation acute ischemic stroke due to a large vessel occlusion patients transferred to 2 comprehensive stroke centers (Stanford, CA, November 2019 to January 2023, and Montpellier, France, January 2015 to January 2017) for mechanical thrombectomy consideration with arterial imaging both at the primary stroke center and on comprehensive stroke center arrival. The primary outcome was interhospital recanalization, determined by comparison of the baseline and posttransfer arterial imaging and defined as revised arterial occlusive lesion scores of 2b to 3. The association between transportation mode (helicopter versus ground) and interhospital recanalization was studied in logistic regression analysis, adjusting for pretransfer IVT use, occlusion site, and transfer duration. Results: Among 520 included patients, 315 (61%) were transferred by helicopter and 259 (50%) received IVT before transfer. Interhospital recanalization rates were similar between helicopter and ground transfers in both the overall cohort (23% versus 19%; P=0.30) and the IVT subgroup (36% versus 33%; P=0.61). Adjusted analyses confirmed no association between helicopter transport and interhospital recanalization (adjusted odds ratio, 1.23 [95% CI, 0.72-2.11]; P=0.44). Favorable 3-month functional outcome (modified Rankin Scale score, 0-2) rates were also similar between helicopter and ground transfers in both unadjusted (35% versus 40%; P=0.29) and adjusted analyses (adjusted odds ratio, 1.12 [95% CI, 0.67-1.88]; P=0.67). Conclusions: In this multicenter observational cohort study, helicopter transfer was not associated with improved interhospital recanalization or favorable functional outcomes compared with ground transport. These findings do not support the hypothesis that vibrations during helicopter transport enhance IVT efficacy.

---

Fichiers liés : Ter Schiphorst Stroke 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/07/2025
• Auteurs : Baptiste AbbarLabreche KarimJacques CadranelMarianne VeyriVéronique MorinFatou Seck ThiamNathalie DesireMarine BaronErell GuillermAlexandre PerrierVincent FalletThomas MaitreAnthony CanellasNadine TarantinoOulfata MzeAssia SamriLisa DejancourtCecilia Nakid-CorderoAurore VozyAlberto PiccaMehdi TouatAmélie GuihotChristos ChouaidKarima MokhtariFranck BielleIsabelle BrocheriouPhilippe RouvierAnita Rodenas OsorioDavid BuobAmira BouzidiYannick MarieJalal AssouadPierre-Yves BoëlleFlorence CouletVincent VieillardJean-Philippe SpanoBrigitte Autran
• Organismes : Centre d'Immunologie et des Maladies Infectieuses
• Publié dans Journal of Thoracic Oncology le 31/10/2020

---

Source